English (UK)
中文版Murthy Chavali
Satya is a discovery stage oncology biotech, focused on first-in-class and best-in-class programs targeting oncogenes and the DDR pathway. The company's multiple programs are at Hit and Hit-Lead stages, and Satya aims to have unique compound profiles that address specific patient populations with potential for bio-marker based patient selection strategies. Satya is seeking licensing and collaboration opportunities for its programs on a geography-specific or global basis.
Responsive Web Design powered by 